*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Therapeutic Potential of Ferric maltol in the Treatment of Iron deficiency anemia: An Evidence-Based Review

Author: , ARIN NATANIA S, RAJA VIDHYA D, KIRAN KUMAR RATHINAM, SARVESH SABARATHINAM
Abstract: Background: The oral formulation of ferrous iron have been extensively used in the management of Iron Deficiency Anaemia. However, oral ferrous products have poor absorption and greater side effects. In addition, existing IV Iron therapy is expensive, invasive and intolerable in many patients with IDA. Oral ferric maltol serves as a novel therapeutic agent which is designated for IDA. The main aim of this review is to express the therapeutic use of Ferric Maltol in IDA as well as multiple co-morbidities like inflammatory bowel disorder. Objectives: To review therapeutic Potential of Ferric maltol in the treatment of Iron deficiency anemia. Methods: A systematic search of literature was performed via Pubmed/Medline, Embase and Cochrane library using key terms such as 'Ferric Maltol, Ferrous, Iron deficiency anemia, Inflammatory Bowel Disease, Pulmonary Hypertension, Heart failure, Chronic Kidney Disease and Anaemia. Studies were included in this review based on the predefined inclusion criteria. Result: Ferric Maltol formulation shows a better alteration for iron. Trials showed substantial changes in the Hb and anaemia and Ferritin concentrations in anaemia patients with multiple co-morbidities like IBD, CKD & PH. Emerging finding indicates for IDA & IBD condition. Ferric maltol appeared to increase the serum levels of iron in terms of normalization or an apparent elevation in terms of the levels of Hb and ferritin. Conclusion: Ferric Maltol is a fairly safe, reliable, cost-effective tolerable oral iron therapy for IDA. Ongoing clinical trials and researches will help to determine the long-term safety and efficacy of Ferric Maltol for enhanced use in future.
Keyword: Ferric maltol, iron deficiency anemia, inflammatory bowel disease, chronic kidney disease.
DOI: https://doi.org/10.31838/ijpr/2021.13.02.444
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free